Since the outbreak of COVID-19, Hadassah Hospital is in a key position at the forefront of patient care, research & development, of innovative drug trials finding effective treatment.

As Israel and the world learn to live through the pandemic era, Hadassah continues to develop and expand its ongoing activity as a centre of excellence in both research and treatment. Our researchers continue to impress the world with discoveries of novel solutions both to COVID-19 and other diseases and share these around our globe. Hadassah’s success in research is down to our approach of “translational” medicine, in which Hadassah excels. This is an interdisciplinary method that takes research in the laboratory straight back to the patient-quickly!

Hadassah’s medical experts are “spreading the word from Jerusalem”. Sharing this advanced applied research from Hadassah with a worldwide network of hospitals and communities including the UK, to extend our help and assistance in the fight against Coronavirus.

In a webinar last year, organised by Hadassah UK and Norwood (the UK’s largest Jewish charity supporting children, families, and people with learning disabilities and autism), Prof. Eitan Kerem, head of the Division of Paediatrics at the Hadassah Hospitals in Jerusalem, offered advice to listeners from 16 countries about how parents can steer their children through the COVID-19 crisis. Read more here.

Today’s Research is Tomorrow’s Care – Hadassah is leading the way in finding and sharing potential treatments quickly:

  • A Hadassah study reveals that newborns are better protected from COVID-19 if their mothers are vaccinated between weeks 27 and 31 of their pregnancies, rather than later on in the third trimester. According to the study authors Dr. Amihai RottenstreichDr. Shay Porat, and Prof. Dana Wolf, when pregnant women are vaccinated during this window of time, their unborn babies receive a higher level of antibodies than those inoculated later in the pregnancy.
  • Dr. Marc Romain, an intensive care specialist at Hadassah Hospital Ein Kerem who treated dozens of patients afflicted with COVID-19, recently travelled to Romania on a special Israeli mission to help Romania deal with the raging pandemic.
  • A major study directed by Prof. Dror Mevorach, head of Hadassah Hospital Ein Kerem’s Internal Medicine B Department, found that out of 5 million Israeli recipients of the Pfizer VOCID-19 vaccine, 136 people developed myocarditis, an inflammation of the heart muscle. Of those cases, the vast majority—129 cases—were mild. The findings were reported in the New England Journal of Medicine on October 6, 2021.
  • Nondiabetic individuals with high blood glucose levels after fasting who contract COVID-19 are at higher risk for developing a serious case of the disease, according to a collaborative study conducted by the Jerusalem College of Technology, Hadassah Medical Organization, Hebrew University-Hadassah Braun School of Public Health and Community Medicine and the Israeli health fund Meuhedet.
  • In the first study of its kind, a Hadassah physician has found that the Pfizer COVID-19 vaccine does not damage the quality or number of a man’s sperm. Dr. Safrai examined the volume, concentration, and movement of the sperm of 60 men in Hadassah’s in vitro fertilization program before and after receiving the COVID-19 vaccination. She found that their sperm count remained unchanged, as did the sperm’s other attributes.
  • Oramed Pharmaceuticals’ novel technology for oral delivery of medication, developed at Hadassah Hospital Ein Kerem, has been used to create an oral COVID-19 vaccine, which will be tested for the first time in Israel.
  • Dr. Rifaat Safadi, director of the Liver Unit at Hadassah Hospital Ein Kerem, has found that his patients who received liver transplants and those with advanced liver disease had a weaker response to the COVID-19 vaccine than is the norm.
  • Hadassah’s humanitarian mission to Argentina took place to share its medical knowledge and to build bridges through health care. DAIA authorities thanked the delegation for choosing Argentina for the implementation of phase III clinical trial of the Brilife vaccine, developed jointly by Hadassah and the Israeli Institute for Biological Research.
  • A Hadassah  study has revealed that pregnant women who were vaccinated against COVID-19 passed their antibodies on to their babies. The level and type of antibodies were suggestive of “being able to block the virus sufficiently,” reports Dr. Dana Wolf, one of the study’s lead researchers and director of the Clinical Virology Unit at Hadassah.
  • Hadassah has vaccinated over 98% of its staff.
  • With the goal of tackling the high levels of COVID-19 within Brazil, as well as fostering scientific exchange in the life sciences, Hadassah and the Federative Republic of Brazil have formed a collaborative partnership in research, protocol sharing, and innovation.
  • Hadassah’s post-COVID-19 outpatient clinic, directed by Dr. Neville Berkman, has treated patients who suffered long-term illness and respiratory problems. It now appears that ‘Long Covid’ is also affecting patients’ hearts, muscles, and/or digestive systems. Some patients experience neurological symptoms ranging from fatigue, dizziness, headache, and loss of smell or taste to cognitive dysfunction and sleep and memory disturbances. Hadassah’s long COVID-19 team, comprising a range of specialists, sees about 15 patients a week to tackle these lingering effects.
  • Hadassah is the first hospital in Israel to offer outpatient treatment to vulnerable COVID-19 patients to prevent the progression of their disease and the need for hospitalisation. The treatment planned for these patients is the one-time antibody therapy called Bamlanivimab, intended for use in the beginning stages of the illness after the patient has tested positive for COVID-19 on a PCR test.
  • Early trials of Allocetra™, an experimental drug developed by Prof. Dror Mevorach, head of one of the COVID-19 units at Hadassah have shown great success in treating seriously ill COVID-19 patients. In the phase one and two trials, the drug had a 90 percent recovery rate. According to Prof. Mevorach, the chief scientific and medical officer at Enlivex, the maker of the drug, “it is useful for serious and critical patients because it can prevent the need to ventilate them, and that’s the major goal. Because the moment you go into ventilation, the entire situation changes, complications rise, and it’s more difficult to treat.” In phase three trials beginning now, the drug will be administered to more than 100 patients.
  • Hadassah opens Israel’s first Paediatric Covid-19 Clinic dedicated to treating Coronavirus in infants.
  • Hadassah, the Israel Institute for Biological Research, and Tera Novel, an Israeli start-up company, have collaboratively developed an innovative antiviral and antibacterial mask, which contains a disinfectant that has been proven to be 99.99 percent effective in killing the coronavirus.
  • In response to the large number of COVID-19 patients suffering from lingering health issues long after they recover from the virus, Hadassah has opened a multidisciplinary clinic at its Pulmonary Institute to monitor and assess their physical and psychological symptoms.
  • Phase I of the first clinical trial with Brilife, the COVID-19 vaccine developed by the Israel Institute for Biological Research, was completed at Hadassah Hospital Ein Kerem on November 26, when the 40th participant received the final dose. Prof. Yossi Karko, director of the centre, explained the success to date: “From monitoring the participants who have been vaccinated so far, we see no unusual side effects, and this seems promising in terms of safety, which is the point of the first stage of the experiment. We can now look forward to the next stage.”
  • The newly established Wohl Centre for Translational Medicine at Hadassah, builds on the extensive R&D infrastructure to improve scientific knowledge about drugs, diseases and their pathways, finding ways to apply this knowledge in a clinical setting to benefit patient care.
  • Hadassah participated in a World Health Organisation (WHO) trial with the drug Remdesivir. Other medicines are being tested to stop the formation of the virus, while others block the virus from penetrating to the body’s cells.
  • Hadassah researchers and SodaStream engineers unveiled a jointly developed innovative respiratory device creating high-flow oxygen systems to treat COVID-19 that help address the critical need for respirators in hospitals and healthcare facilities.
  • Hadassah’s clinical trial enrich COVID-19-specific “T” cells of the immune system from recovered patients to treat patients who are severely ill with the virus. Plasma collected from recovered COVID-19 patients is also used for treatment.
  • Hadassah is studying blood samples of COVID-19 to identify biomarkers that make people more susceptible or resistant to the disease.
  • More than 30% of COVID-19 patients suffer from blood clots creating lethal blockages in the lungs, kidneys, heart and brain. Hadassah has found the mechanism that causes them. They are now working on a new way to dissolve these blood clots. Hadassah believes if the drug works to reduce blood clots in COVID-19, it will vastly reduce the numbers of patients needing respirators.


Click here to read more about the cutting-edge research coming out of Hadassah Hospital

Thanks to the generosity of our donors, our Hospital has been able to cope with Israel’s most acute cases of the Coronavirus at the quickly established COVID-19 Units at Hadassah. Our current infrastructure continues to be critical for Jerusalem and Israel today.

With your help we can ensure that our medical teams have the essential equipment to treat, research and share this information globally including the UK.

With support from our valued donors, we are already saving lives and infra structure around the world to help mitigate the impact of Covid-19

Click here to support our urgent appeal.